Christine Tkaczyk

Director, Microbial Antibody Technology · AstraZeneca · company speakers →

Christine Tkaczyk is Director in the Microbial Antibody Technology group within Early Vaccines & immune Therapies at AstraZeneca, Gaithersburg, USA. At AstraZeneca, she spent 18 years developing monoclonal antibodies for serious bacterial infections. More recently, she expanded her research to develop mRNA platform for delivering diverse formats of monoclonal antibodies in vivo.

Is this you? Claim this profile →

No public contact links on file.

Speaking history

mRNA-Based Therapeutics Summit

20 July 2026 Boston, United States

Sectors

healthcare_medtech_pharma

Sourcing speakers for your event?

Browse the speaker directory →